News

EGb 761® recommended for the treatment of mental problems caused by long COVID

Stethoscope on cardiogram

In a recently published long COVID review, the authors present recommendations for GP care based on a systematic literature review and personal therapeutic experience: EGb® 761 is recommended for the treatment of mental problems caused by long COVID.

A milestone in phytomedicine: clinical trial proves efficacy of Silexan® in depression

Stethoscope on cardiogram

A recent publication reports on our international clinical trial to demonstrate the efficacy and safety of Silexan®, a proprietary lavender oil preparation, in the treatment of mild to moderate depressive episodes.

Schwabe Group now top sponsor of important natural-product research congress

Schwabe Tree

The Schwabe Group together with Bayer has become the silver sponsor of the International Congress on Natural Products Research. The congress is organized by seven independent professional societies from America, Asia and Europe. It brings together more than 1,000 scientists from all over the world.

Umckaloabo Foundation: We are helping our “Little Five” get bigger!

Njabulo Khatha during primary school

The Umckaloabo Foundation has set itself the goal of giving children and young people in southern Africa a future with prospects and a self-determined life through sustainable, successful educational projects. This year the Umckaloabo Foundation is helping five elementary schools in the Eastern Cape.

Treatment with EPs® 7630 reduces illness absence from childcare due to acute bronchitis

Stethoscope on cardiogram

Recently, a meta-analysis was published which considered and analyzed the available randomized, placebo-controlled clinical trials with EPs® 7630 in children and adolescents. The question was to what extent treatment with EPs® 7630 for acute bronchitis reduces the average time of illness absence from kindergarten, school, or training.

Schwabe Group reduces carbon footprint by 14 percent

Road sign with decreasing CO2 emissions

The Schwabe Group reduced its international carbon footprint in Scopes 1 and 2 by 14% or 6,800 t in 2022 compared to 2021 values. Our current global carbon footprint showed emissions totaling 48,284 t CO2e. This means we have achieved a major interim milestone along the path towards cutting Scope 1 and 2 CO2 emissions in half by 2030 versus baseline.

Schwabe Group matches donations - €110,658 for the School In Africa program!

Olaf Schwabe, CEO of the Schwabe Group, presents Mwawi Shaba, the project manager for the St. Steven's School in Malawi, the donation from the Africa Runners."

An impressive €60,568 came together as the total amount which Africa Runners raised for the St. Steven’s Secondary School in Malawi in 2023. And since the Schwabe Group matches donations up to a maximum of €50,000, the Africa Runners were proudly able to contribute €110,568.

Conference of German Society for Gastroenterology: Menthacarin® shows relevant treatment effects

Stethoscope on cardiogram

At the 77th annual conference of the DGVS in Hamburg Prof. Dr. Ahmed Madisch held an oral presentation on our proprietary combination of peppermint and caraway oil Menthacarin®. In a meta-analysis, Menthacarin® shows clinically relevant treatment effects on epigastric pain, flatulence and/or bloating.

Schwabe Group Germany converted vehicle fleet to e-cars only

The vehicle fleet of the Schwabe Groupü germany has converted to e-cars only

In September 2023 the last IC engine was retired from the vehicle fleet, so the fleet of the two Karlsruhe locations consists exclusively of e-cars that are charged with green electricity.

14.02.2023 - A clinical trial assessed the use of EPs® 7630 as Syrup and Solution in children ages one to five with acute bronchitis. The study found that an improvement in health status and complaints were comparably positive in treatment with EPs® 7630. Both dosage forms were equally safe and well-tolerated in children between the ages of one and five.  

More

26.01.2023 - In 2022, the Schwabe Group Germany converted to green electricity at both of its sites in Karlsruhe. This means that all of the electricity obtained from our power supplier comes from renewable kinds of energy. 

More

15.01.2023 - We are pleased to announce a new research agreement with Dalhousie University from Nova Scotia, Canada. In conjunction with Prof. Vasantha Rupasinghe, one of the leading experts in the field of research about the haskap berry, we will analyze novel extraction methods for producing a special extract with enriched active substances (cyanidin-3-glucoside).

More

05.12.2022 - We are pleased to announce that our high-quality pharmaceutical Refluthin® was launched in Belgium. New Refluthin® chewable tablets have twice the effect on heartburn: the mineral-based acid buffers quickly soothe acid-related gastric discomfort such as heartburn and acid regurgitation.

More

21.11.2022 - Our Web Content Management System (WCMS) is one of the winners of this year's SplashAwards. In the category "Healthcare", the Schwabe Group came out as the best Drupal project..

More

16.11.2022 - Schwabe Group Germany received an award this year once again for its commitment to offering professional training! The business magazine Capital gave us full marks in the fields of mentorship, innovative teaching methods, and excellent future prospects!

More

13.10.2022 - For over 10 years Nature’s Way has been quietly supporting Feed the Children – a non-profit organization which envisions a world in which no child goes to bed hungry.

More

16.09.202 - The Dr Willmar Schwabe Award, which is sponsored by our company, was first presented by the GA – Society for Medicinal Plant and Natural Product Research, one of the world’s most important scientific societies in phytoresearch, back in 1961. This year Dr Simone Moser from Ludwig Maximilian University of Munich, was awarded for her innovative and pioneering research.

More

14.09.2022 - At the 39th Annual Healthcare Advertising Award ceremony, Schwabe’s explainer video on the topic of mild cognitive impairment (MCI) won over the jury and brought home a Merit Award.

More

25.08.2022 - The Pegaso® line consists of probiotics, prebiotics, herbal ingredients and vitamins, and it represents a distinctive therapeutic approach to specific GI complaints (diarrhea, constipation, etc.). At the same time, it is ideal for treating a variety of problems in children and adults.

More

29.07.2022 - In a recent review, Bartova et al.* present findings that Silexan® has beneficial effects also on co-occurring depressive symptoms in patients with underlying anxiety and anxiety disorders. The data were collected from patients with anxiety in several clinical trials and have now been recompiled and statistically analyzed. 

More

08.06.2022 - As part of the Schwabe Phyto Innovation Challenge, we are pleased to announce a new research agreement with the department of pharmacognosy at the University of Vienna. Under the guidance of chair Dr. Judith M. Rollinger, we will spend the next three years working on a joint project to analyze the positive effects of herbal extracts and combinations of natural substances on age-related diseases.

More

 

 

07.07.2022 - As part of the Schwabe Phyto Innovation Challenge, we have now successfully launched a collaborative project: Dr. Simone Moser and her team will analyze phylloxanthobilins; this group of substances was discovered in recent years and is thought to have potentially positive effects on arteriosclerosis. The process of the blood vessels hardening is responsible for the majority of cardiovascular problems in older people.

More

13.04.2022 - We are pleased to announce that our high-quality pharmaceutical Gaspan® was launched in Italy. Recurrent or persistent gastrointestinal complaints such as flatulence, mild cramps and a feeling of fullness impair quality of life. Gaspan® works with a unique combination of peppermint oil and caraway oil and has a targeted effect where the discomfort is caused: in the gut. 

More